📰 BloombergBloombergDoubao · 实盘可交易 · 做空市场:美股▲ 赚 +0.85% · 已结算把握 6/10
北京时间·🕒 发布 04:54:40·⟳ 抓取 04:58:26 +3m46s·⚡ 决策 10-21 05:03:56 +5m30s·6.7 天前
直觉外科Q3达芬奇手术量增速降至约14%，全年手术量增长上沿被削至15%，盘后一度大跌
直接负面财报催化明确，盘后正式常规时段尚未完成重定价；但EPS超预期、盘后已显著下跌且波动剧烈，因此仅以小仓、限价和严格止损做空。
📄 原文Bloomberg↗ 原文
Intuitive Surgical Inc. narrowed the range of its procedure growth outlook for the full year after reporting slowing gr…
▲ 赚 +0.85%入场 10-20 盘后首笔 @407.28 → 离场 10-21 常规开盘 @402.50
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(做空:价格在入场线下方)、绿底 = 亏
💡 交易逻辑手术量四年最弱且削增长上沿，盘后重定价未完
怎么做空 开盘做空 不低于昨收 +10%（低于下限不成交）
怎么平空 止盈 -5%(半仓)/-10%(清仓) · 止损 +6% · 时间止损 3日
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做空 ISRG.US Intuitive Surgical
5 个交易日均已收盘,数据完整 · 美股含盘前盘后(灰底:美东 04:00 至收盘后 4 小时)
- 发布 10-21 04:54 北京(美东 10-20 16:54)
- 入场 10-21 04:58 北京(美东 10-20 16:58) · 盘后首笔 @407.28
- 抓取 10-21 04:58 北京(美东 10-20 16:58)
- 决策 10-21 05:03 北京(美东 10-20 17:03)
- 离场 10-21 21:30 北京(美东 10-21 09:30) · 常规开盘 @402.50
时间轴只含交易时段(午休、隔夜已压缩);横轴为北京时间,悬停看当地时间;蓝虚线 = 纸面入场价;建仓日图红线在昨收上方、绿线在下方
成交明细 · 纸面
做空 ISRG.US Intuitive Surgical
| 收益状态 | +0.85% 已平仓 |
|---|---|
| 进场成交 | 2026-10-20 · 盘后首笔 · 10-21 04:58 北京 · @407.283 |
| 离场成交 | 2026-10-21 · 常规开盘 · @402.495 |
| 毛收益 | +1.18% |
| 成本 | +0.32% |
| 净收益 | +0.85% |
| 计入收益 | +0.86% |
| 建仓日 | 2026-10-20 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-27 21:11
研究档案
结论摘要
直觉外科盈利 beat 但核心达芬奇手术量增速降至四年低点，并削减全年增长上沿；市场对增长质量的负面反应已在盘后显现，参考2026年Q2同类手术量担忧后的连续下挫，次日开盘仍有延续做空窗口。
消息传播链
- 公司发布Q3业绩，披露总手术量增长约15%、达芬奇手术量增长约14%及2026年展望。
- Bloomberg明确报道公司收窄全年手术量增长展望，并指盘后股价下跌约11%。市场反应:Futu盘后16:58 EDT报407美元，较常规收盘438美元下跌7.08%，盘后区间378-451美元。
关键理由
- 全年达芬奇手术量增长区间收窄至14%-15%，确认医院支出、GLP-1替代和竞争压力正在削弱核心增长指标。
- 2026年Q2同为业绩超预期但手术量前景走弱，ISRG首个常规交易日下跌14.15%、第五日仍下跌17.48%，显示市场会持续下修估值。
主要风险
- 调整后EPS 3美元显著高于预期2.6美元，若电话会强调利润率或2027年需求改善，盘后超跌可能快速反弹。
- 盘后区间从378美元反弹至407美元，说明空头波动和回补风险很高，若开盘跌幅不足或高开应放弃追空。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-10-20 · 影响 weakens
调整后EPS为3美元、高于预期2.6美元，公司仍保持14%-15%增长区间而非全面下修，构成显著反弹风险。
检索:Intuitive Surgical Q3 2026 adjusted EPS beat margins raised positive guidance 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-20 · 影响 none
竞争关系存在但没有可量化的订单转移或同业上修，不能用竞争对手做多腿对冲，也不削弱ISRG自身负面催化。
检索:ISRG competitors JNJ Medtronic Stryker CMR Surgical direct revenue benefit Q3 2026 原文 ↗ - 做空前查反向 · 来源 kb_search · 影响 none
内部KB检索服务连接失败，未取得新增反方研报；该工具失败不作为事实证据。
检索:Intuitive Surgical ISRG Q3 2026 procedure growth guidance analyst counterview
先例如何影响了这次决策
对本次决策的影响:支持小仓做空ISRG，但因盘后已从-13.7%低点收窄至-7.1%且EPS大超预期，设置-10%以内的开盘追空限制、5%/10%止盈和-6%止损。
方向:最相似的2026年Q2手术量增长担忧先例明确偏空，首个常规交易日-14.15%、第5日-17.48%；其余正反先例说明真正驱动股价的是手术量增长预期而非单纯EPS。
涨幅量级:只有2026年Q2一条高相似且锚可信的负面前例，足以校准方向和5%-10%的延续空间，但样本很薄，不能按Q2全部跌幅机械外推。
形态:2026年Q2负面增长惊喜后无快速修复；普通beat或正面增长惊喜则方向相反，当前更接近Q2负面模式。
历史先例(按相似度)
- 相似度 9/10 ISRG 2026-07-16 2026年Q2业绩beat但手术量/下半年增长前景引发担忧，盘后双位数下跌。 原文 ↗
事件后 +1日 -14.2% · +2日 -12.2% · +3日 -13.0% · +4日 -15.3% · +5日 -17.5%
相似度依据:同一公司、同一盘后财报相位，同样是业绩超预期但市场聚焦手术量增长和指引压力。
经验:盈利beat不能对冲核心手术量增长担忧，负面反应在首个常规交易日后仍有延续。 - 相似度 5/10 ISRG 2026-04-21 2026年Q1业绩超预期但盘后小幅走弱，随后常规盘反弹。 原文 ↗
事件后 +1日 +7.2% · +2日 +6.1% · +3日 +6.8% · +4日 +4.4% · +5日 +3.4%
⚠来源层级不符(声明issuer/实为media) — 该行涨幅别用来定止盈止损
相似度依据:同一公司盘后财报且盘后小跌，但当前事件的指引下修和竞争压力更强。
经验:一般性业绩beat后的盘后小跌未必延续，需有明确增长指引恶化才适合做空。 - 相似度 4/10 ISRG 2025-10-21 2025年Q3收入和手术量强劲、增长展望提高，盘后大涨。 原文 ↗
事件后 +1日 +13.9% · +2日 +19.1% · +3日 +18.1% · +4日 +19.1% · +5日 +17.9%
相似度依据:同为Q3盘后财报，但那次是手术量强劲和指引上修，方向与当前相反。
经验:ISRG股价对手术量增长预期高度敏感，正向增长惊喜会带来显著重估；这反向支持当前手术量下修的空头逻辑。 - 相似度 4/10 ISRG 2026-01-22 2025年Q4业绩超预期，股价盘后上涨但后续五日回落。 原文 ↗
事件后 +1日 -0.3% · +2日 +0.6% · +3日 -0.1% · +4日 -0.7% · +5日 -3.5%
⚠来源层级不符(声明issuer/实为media) — 该行涨幅别用来定止盈止损
相似度依据:同一盘后财报相位，但为正面beat，缺少当前的增长指引下修冲击。
经验:缺少核心增长负面惊喜时，财报beat难以持续驱动方向性行情。
工具执行结果 · 成功 16 · 降级 1 · 失败 1 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`intuitive surgical 2026 q3 earnings procedure growth 14% guidance narrowed 14%-15% | isrg da vinci q3 2026 weak procedure demand postmarket shares fell 11%`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消 - stock_quote 成功 stock_tools HTTP · 422 ms
{ - web_search 成功 doubao_search · 1,484 ms
豆包搜索结果（原始查询:Intuitive Surgical Q3 2026 results procedure growth outlook 14% 15% shares fall postmarket October 20 2026；API SearchType:web） - web_search 成功 doubao_search · 1,307 ms
豆包搜索结果（原始查询:Intuitive Surgical earnings stock fell after hours procedure growth guidance cut historical reaction October 2024 2025；API SearchType:web） - search_case_library 成功 stock_tools HTTP · 21 ms
{"result": "search_case_library「ISRG.US」—— 与这些标的相关、事件类型=财报/业绩预告的自家决策案例(本页 10 条,该标的全历史相关记录共 43 条；ENTER 只按该标的自己的腿统计):\n◆ ISRG.US：相关历史决策 43 条 · 其中该标的 ENTER 2 条(4.7%) · 已结算 2 笔 · 胜率 50% · 中位 -1.73% · 均值 -1.73% ⚠️只有 2 笔,样本太薄,只能当线索不能当规律\n↑ 胜率/收益口径:ENTER 当日之后 T+1 开盘入场、次日开盘出场,做空腿已按方向取反(所以正数=这个方向做对了)。统计的只有★那 - web_search 成功 doubao_search · 535 ms
web_search「site:isrg.intuitive.com/news-releases "Intuitive Announces Second Quarter Earnings" 2026 July 16」无结果。 - web_search 成功 doubao_search · 473 ms
web_search「site:isrg.intuitive.com/news-releases "Intuitive Announces First Quarter Earnings" 2026 April」无结果。 - web_search 成功 doubao_search · 420 ms
web_search「site:isrg.intuitive.com/news-releases "Intuitive Announces Fourth Quarter Earnings" 2026 January」无结果。 - web_search 成功 doubao_search · 435 ms
web_search「site:isrg.intuitive.com/news-releases "Intuitive Announces Third Quarter Earnings" 2025 October 21」无结果。 - web_search 成功 doubao_search · 1,453 ms
豆包搜索结果（原始查询:Intuitive Surgical Q2 2026 earnings procedure growth stock fell 16% July 2026 Reuters；API SearchType:web） - web_search 成功 doubao_search · 1,501 ms
豆包搜索结果（原始查询:Intuitive Surgical Q1 2026 earnings stock procedure growth guidance shares April 2026；API SearchType:web） - web_search 成功 doubao_search · 1,729 ms
豆包搜索结果（原始查询:Intuitive Surgical third quarter 2025 earnings October 21 2025 procedure growth shares reaction；API SearchType:web） - web_search 成功 doubao_search · 1,313 ms
豆包搜索结果（原始查询:Intuitive Surgical fourth quarter 2025 earnings January 22 2026 shares reaction procedure growth guidance；API SearchType:web） - web_search 成功 doubao_search · 1,299 ms
豆包搜索结果（原始查询:Intuitive Surgical Q4 2024 earnings January 21 2025 stock falls procedure growth guidance；API SearchType:web） - web_search 成功 doubao_search · 1,267 ms
豆包搜索结果（原始查询:Intuitive Surgical Q3 2024 earnings October 17 2024 stock reaction procedure growth；API SearchType:web） - event_study 降级 stock_tools HTTP · 27 ms
1 precedent(s) rejected; 0 benchmark warning(s) - kb_search 失败 stock_tools HTTP · 57 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - validate_order 成功 stock_tools HTTP · 8 ms
{
原文全文
展开原文 · 1,490 字
Intuitive Surgical Inc. narrowed the range of its procedure growth outlook for the full year after reporting slowing growth for the fourth straight quarter, keeping alive concerns over increasing competition and reduced hospital spending.
Procedures performed with the company’s da Vinci surgical robots rose around 14% in the third quarter from a year ago, the weakest growth in four years. The company now expects da Vinci procedure growth between 14% and 15% this year, compared to a previous expectation of as much as 15.5%.
Competition is intensifying in the sector, with Johnson & Johnson and Medtronic Plc both launching their own robotic products and Stryker Corp. investing $400 million in soft-tissue robotic firm CMR Surgical.
Changes to Affordable Care Act subsidies have impacted procedure growth in the US, along with the growing uptake of GLP-1s, which has slowed demand for bariatric surgery.
Company shares fell 11% in postmarket trading.
Intuitive, based in Sunnyvale, California, reported adjusted earnings per share of $3, compared to estimates of $2.6.
Medical technology companies have been challenged this year by changes to the Affordable Care Act and Medicaid programs, which raised concerns that procedures would slow down as coverage falls. Device recalls, cyber attacks and a dearth of product launches further dented investor confidence.
Next year looks brighter for the sector, heading into 2027 with the strongest growth outlook in more than two years.
Procedures performed with the company’s da Vinci surgical robots rose around 14% in the third quarter from a year ago, the weakest growth in four years. The company now expects da Vinci procedure growth between 14% and 15% this year, compared to a previous expectation of as much as 15.5%.
Competition is intensifying in the sector, with Johnson & Johnson and Medtronic Plc both launching their own robotic products and Stryker Corp. investing $400 million in soft-tissue robotic firm CMR Surgical.
Changes to Affordable Care Act subsidies have impacted procedure growth in the US, along with the growing uptake of GLP-1s, which has slowed demand for bariatric surgery.
Company shares fell 11% in postmarket trading.
Intuitive, based in Sunnyvale, California, reported adjusted earnings per share of $3, compared to estimates of $2.6.
Medical technology companies have been challenged this year by changes to the Affordable Care Act and Medicaid programs, which raised concerns that procedures would slow down as coverage falls. Device recalls, cyber attacks and a dearth of product launches further dented investor confidence.
Next year looks brighter for the sector, heading into 2027 with the strongest growth outlook in more than two years.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
b203cb8582· 2026-10-21 05:03 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前